Robert Orlowski

2.4k total citations · 1 hit paper
35 papers, 673 citations indexed

About

Robert Orlowski is a scholar working on Obstetrics and Gynecology, Oncology and Reproductive Medicine. According to data from OpenAlex, Robert Orlowski has authored 35 papers receiving a total of 673 indexed citations (citations by other indexed papers that have themselves been cited), including 23 papers in Obstetrics and Gynecology, 19 papers in Oncology and 12 papers in Reproductive Medicine. Recurrent topics in Robert Orlowski's work include Endometrial and Cervical Cancer Treatments (23 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Genetic factors in colorectal cancer (8 papers). Robert Orlowski is often cited by papers focused on Endometrial and Cervical Cancer Treatments (23 papers), Cancer Immunotherapy and Biomarkers (17 papers) and Genetic factors in colorectal cancer (8 papers). Robert Orlowski collaborates with scholars based in United States, Japan and Spain. Robert Orlowski's co-authors include Vicky Makker, Matthew H. Taylor, Carol Aghajanian, Corina E. Dutcus, Antonio Casado, Margarita Romeo, Ana Oaknin, Mark Messing, Allen Lee Cohn and Raquel Bratos and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Robert Orlowski

30 papers receiving 667 citations

Hit Papers

Lenvatinib Plus Pembrolizumab in Patients With Advanced E... 2020 2026 2022 2024 2020 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer
    2020 359 citations Vicky Makker, Matthew H. Taylor et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert Orlowski United States 11 399 279 215 160 108 35 673
Raquel Bratos Spain 8 327 0.8× 222 0.8× 229 1.1× 92 0.6× 68 0.6× 13 609
Florine A. Eggink Netherlands 11 491 1.2× 291 1.0× 201 0.9× 141 0.9× 357 3.3× 15 830
Kyaw Aung Canada 11 534 1.3× 215 0.8× 146 0.7× 137 0.9× 152 1.4× 21 806
Isabelle Laure Ray-Coquard France 15 625 1.6× 101 0.4× 423 2.0× 103 0.6× 86 0.8× 110 852
Arkhipov Alexander Russia 3 352 0.9× 295 1.1× 115 0.5× 58 0.4× 94 0.9× 4 629
Richard A. Boothby United States 6 323 0.8× 108 0.4× 291 1.4× 120 0.8× 60 0.6× 7 600
P. Iyengar Canada 12 152 0.4× 154 0.6× 130 0.6× 104 0.7× 30 0.3× 24 517
Elisabeth Janschek Austria 10 318 0.8× 173 0.6× 200 0.9× 73 0.5× 31 0.3× 17 687
Nicole Kelbick United States 7 260 0.7× 136 0.5× 75 0.3× 95 0.6× 63 0.6× 9 522
Steven DeCesare United States 9 243 0.6× 260 0.9× 240 1.1× 86 0.5× 80 0.7× 13 695

Countries citing papers authored by Robert Orlowski

Since Specialization
Citations

This map shows the geographic impact of Robert Orlowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Orlowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Orlowski more than expected).

Fields of papers citing papers by Robert Orlowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Orlowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Orlowski. The network helps show where Robert Orlowski may publish in the future.

Co-authorship network of co-authors of Robert Orlowski

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Orlowski. A scholar is included among the top collaborators of Robert Orlowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Orlowski. Robert Orlowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Young, Kate, Vimalanand S. Prabhu, Christina Ljungcrantz, et al.. (2024). Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden. Journal of Medical Economics. 27(1). 483–491.
4.
5.
Monberg, Matthew, Vassiliki Karantza, Konstantinos Tryfonidis, et al.. (2024). A Narrative Review of the Clinical, Humanistic, and Economic Value of Pembrolizumab-Based Immunotherapy for the Treatment of Breast and Gynecologic Cancers. Oncology and Therapy. 12(4). 701–734. 1 indexed citations
6.
7.
Makker, Vicky, Carol Aghajanian, Allen Lee Cohn, et al.. (2023). A Phase Ib/II Study of Lenvatinib and Pembrolizumab in Advanced Endometrial Carcinoma (Study 111/KEYNOTE-146): Long-Term Efficacy and Safety Update. Journal of Clinical Oncology. 41(5). 974–979. 25 indexed citations
8.
Yonemori, Kan, Mayu Yunokawa, Kimio Ushijima, et al.. (2022). Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE‐775. Cancer Science. 113(10). 3489–3497. 17 indexed citations
9.
10.
11.
Colombo, N., Domenica Lorusso, Yong‐Mi Kim, et al.. (2021). 145 Characterization of adverse reactions in patients with advanced endometrial cancer (aec) receiving lenvatinib + pembrolizumab (Study 309/KEYNOTE-775). INFM-OAR (INFN Catania). A78.1–A78. 2 indexed citations
12.
Colombo, Nicoletta, Domenica Lorusso, A. Casado Herráez, et al.. (2021). 726MO Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician’s choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775). Annals of Oncology. 32. S729–S730. 18 indexed citations
13.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2021). 796P Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111. Annals of Oncology. 32. S760–S760. 1 indexed citations
14.
Gorp, Toon Van, Mansoor Raza Mirza, Alain Lortholary, et al.. (2021). ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.. Journal of Clinical Oncology. 39(15_suppl). TPS5608–TPS5608. 11 indexed citations
15.
16.
Makker, Vicky, Matthew H. Taylor, Carol Aghajanian, et al.. (2020). Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer. Journal of Clinical Oncology. 38(26). 2981–2992. 359 indexed citations breakdown →
17.
Zinzani, Pier Luigi, В Я Мельниченко, Krimo Bouabdallah, et al.. (2020). Pembrolizumab Monotherapy in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): 3-Year Follow-up of the Keynote-170 Study. Blood. 136(Supplement 1). 42–43. 1 indexed citations
18.
Kline, Justin, James Godfrey, Girish Venkataraman, et al.. (2018). PD-L1 Gene Alterations Identify a Unique Subset of Diffuse Large B Cell Lymphoma That Harbors a T Cell Inflamed Phenotype. Blood. 132(Supplement 1). 673–673. 2 indexed citations
19.
Orlowski, Robert, David L. Porter, & Noelle V. Frey. (2016). The promise of chimeric antigen receptor T cells (CARTs) in leukaemia. British Journal of Haematology. 177(1). 13–26. 15 indexed citations
20.
O’Connor, Owen A., André Goy, Robert Orlowski, et al.. (2008). A phase I-II trial of the kinesin spindle protein (KSP) inhibitor SB-743921 on days 1 and 15 every 28 days in non-Hodgkin or Hodgkin lymphoma. Journal of Clinical Oncology. 26(15_suppl). 8539–8539. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raquel Bratos Breakdown of academic impact, for papers by Florine A. Eggink Breakdown of academic impact, for papers by Kyaw Aung Breakdown of academic impact, for papers by Isabelle Laure Ray-Coquard Breakdown of academic impact, for papers by Arkhipov Alexander Breakdown of academic impact, for papers by Richard A. Boothby Breakdown of academic impact, for papers by P. Iyengar Breakdown of academic impact, for papers by Elisabeth Janschek Breakdown of academic impact, for papers by Nicole Kelbick Breakdown of academic impact, for papers by Steven DeCesare
Rankless by CCL
2026